# EDGAR Filing Document

**Accession Number:** 0001636651
**File Stem:** 0001193125-26-174064
**Filing Date:** 2026-4
**Character Count:** 2421
**Document Hash:** f7a71fb16a4569fa62eda69b3ad28c90
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-174064.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001193125-26-174064

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ovid Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001636651
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465270895
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-776-4381

**MAIL ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**OVID THERAPEUTICS INC.** 

441 Ninth Avenue, 14th Floor

New York, New York 10001

April 23, 2026

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Attn: | Ms. Lauren Hamill |
| Re: | **Ovid Therapeutics Inc.** |
|  | **Registration Statement on Form S-3 (File No. 333- 295218)** |
|  | **Request for Acceleration of Effective Date** |

---

Ms. Hamill:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "***Registrant***") hereby requests that the Securities and Exchange Commission (the "***Commission***") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333- 295218) (the "***Registration Statement***") to become effective on April 24, 2026 at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.

Once the Registration Statement has been declared effective, please confirm that event with Jaime L. Chase of Cooley LLP at (202) 728-7096 or Laura Berezin of Cooley LLP at (650) 843-5128.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Ovid Therapeutics Inc. | Ovid Therapeutics Inc. |
| By: | /s/ Jeff Rona |
|  | Jeff Rona |
|  | *Chief Business and Chief Financial Officer* |

---

cc: Jeff Rona, Ovid Therapeutics Inc. Laura Berezin, Cooley LLP <br> Jaime L. Chase, Cooley LLP